Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043359
Filing Date
2025-05-14
Accepted
2025-05-14 16:30:51
Documents
46
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241639-10q_citius.htm   iXBRL 10-Q 358787
2 CERTIFICATION ea024163901ex31-1_citius.htm EX-31.1 10106
3 CERTIFICATION ea024163901ex31-2_citius.htm EX-31.2 9965
4 CERTIFICATION ea024163901ex32-1_citius.htm EX-32.1 4349
  Complete submission text file 0001213900-25-043359.txt   2498419

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctor-20250331.xsd EX-101.SCH 22586
6 XBRL CALCULATION FILE ctor-20250331_cal.xml EX-101.CAL 16620
7 XBRL DEFINITION FILE ctor-20250331_def.xml EX-101.DEF 109927
8 XBRL LABEL FILE ctor-20250331_lab.xml EX-101.LAB 202560
9 XBRL PRESENTATION FILE ctor-20250331_pre.xml EX-101.PRE 119804
48 EXTRACTED XBRL INSTANCE DOCUMENT ea0241639-10q_citius_htm.xml XML 154064
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-41534 | Film No.: 25946287
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)